Plain-English translation of NCT04750616 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether — a form of vitamin B3 — can reduce heart and kidney damage that sometimes happens during heart surgery. The study will give some patients and others a placebo (dummy pill) on the day of surgery and for two days afterward. Researchers want to see if this medication can help prevent complications in people undergoing valve replacement, bypass surgery, or combination procedures.
Heart surgery with a heart-lung machine can sometimes injure the heart and kidneys, especially in patients who already have heart or kidney problems. Doctors are exploring whether this medication might protect these organs during and after the procedure.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will be randomly assigned to take either or a placebo on your surgery day and again on the two days after surgery. You'll be followed for health changes related to your heart and kidney function. The entire study lasts about 42 months, with most of that time spent enrolling patients; you personally will be involved for a few days around your surgery plus a follow-up period.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Kaiser Permanente
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), Beth Israel Deaconess Medical Center
Enrollment target
~304 participants
Started
September 2021
Primary completion
April 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ali Poyan Mehr, MD
Kaiser Permanente
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.